• Abzena, the integrated CDMO and CRO specializing in complex biologics and bioconjugates, has named Geoffrey Glass as its new CEO.
• Bringing three decades of life sciences leadership, Glass aims to build on recent operational successes and accelerate Abzena’s growth trajectory.

Abzena today (July 22, 2025) announced the appointment of Geoffrey Glass as CEO, effective immediately. Glass has served as chairman of the board since 2022.

Bringing 30 years of life sciences experience spanning innovative biopharma and service organizations, Glass has played a significant role in shaping the CDMO industry over the past 15 years. His previous executive roles include leadership positions at EY Consulting, Valeant Pharmaceuticals (now Bausch Health), Patheon (now Thermo Fisher Scientific), Sancilio Pharmaceuticals, and KINICITI.

“Over the past few years, Abzena has made incredible progress driving operational execution and strengthening our unique scientific capabilities,” said Glass. “These efforts have fueled significant growth, delighting our customers. Having worked closely with the team as chairman, I am honoured to take on the CEO role and continue advancing our momentum. I look forward to collaborating with our talented employees to better support our customers and their patients.”

The board of directors expressed confidence in Glass’s leadership. They said: “Geoff has been a steady and strategic leader as chairman. His operational focus, customer-centric approach, and deep business understanding position him well to guide Abzena’s next phase. We are confident in his ability to build on the company’s solid foundation.”